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Abstract: Castleman’s Disease (CD) is a rare lymphoproliferative disorder accompanied by marked systemic inflammatory 
response. Morphological diagnosis of CD requires biopsy of the whole of the involved lymph node tissue. Three histologic 
variants have already been described in CD morphology (hyaline vascular, plasma-cell, and mixed). In this study, we report a 
case of a multicentric Castleman’s disease of the plasma cell variant type with negative Herpes Virus 8. The clinical 
presentation of this patient was of systemic amyloidosis as a result of both a delayed diagnosis and medical management.  
Previously described cases of CD with secondary amyloidosis have been of the localized type. Regardless, long-standing 
clinical remission of CD by cytotoxic drugs and anti-CD20 antibody therapy was achieved, but the nephrotic syndrome 
remained irreversible. 
 
Introduction 
The first case of Castleman’s disease was described  by  
Dr Benjamin Castleman in 1954 and it  is a rare and poorly 
understood lymphoproliferative disorder  [1,2]. 
Castleman’s disease may occur at any age with no sex 
predominance. Clinical manifestations range from 
asymptomatic discrete lymphadenopathy to recurrent 
episodes of diffuse lymphadenopathy associated with   
severe systemic symptoms in some patients   [2, 3].   
Infectious diseases:  TB, HIV, cat scratch disease and 
tumours like neurofibromatosis lipoma, thymomoa, non-
Hodgkin lymphoma are all differential diagnoses of CD.   
 
Our case study is that of a male patient who presented 
to our hospital with complicated longstanding systemic 
inflammation in which the underlying cause “Castleman’s 
disease” was diagnosed after many years of illness. 
 
Case presentation: 
In 1998,  a 48-year-old male of Mediterranean origin 
presented to the infectious disease clinic with a three 
week history of mild fever (38.1ºC), weight loss (5-6 kg), 
elevated CRP, but other laboratory tests were within 
normal limits (table 1). Immunological tests for ANA, anti-
DNA, ANCA, anti-MPO, anti-smooth muscle and anti-
mitochondrial antibodies were all negative. Two weeks 
later he presented again with fever (41.9) ºC and was re-
admitted for further evaluation. 
 
On admission he was anaemic (Hgb 69 g/l) and 
complained of left sided weakness.  Head and spine CT 
and MRI results were normal, however lumbar puncture 
showed a slight increase of leukocytes with normal 
protein.  The polymerase chain reaction (PCR) and culture 
of bone marrow, liquor and urine for tuberculosis were all 
negative.  Previously the patient had completed a course 
of antibiotics (cefuroxime, doxycycline and imipenem) for 
ex juvantivus treatment without improvement.  
 
Abdomen CT revealed an enlarged spleen and lymph 
nodes near the kidney hilus, whereas the chest CT showed 
only a diffuse parenchymal process in lung bases with no 
visible masses.  
 
During the next two years, the patient experienced a 
persistent inflammatory reaction on serum protein 
electrophoresis and persistent high serum alkaline 
phosphatase (ALP) and glutamyltransferase (GT), table 1. 
Follow up CT and MRI showed slightly enlarged lymph 
nodes (1 cm in size) of para-aortic and liver hilus where 
fine needle biopsies showed no evidence of malignancy.  
Chromogranin A, carcinoembryonic antigen, and alpha-
feto protein tests were all normal. 
Table 1   Laboratory findings during follow up evaluation, up to 2 
months post renal transplantation, 2007  
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Hgb (11.5-
18.6g/dL) 
11.9 10.3  11.3  13.111.712.6 12.6
Leucocytes (4-10x10
9/L)  8.7  8.2 6.1   7.3 7   
CRP  (<5mg/L)  312  34 64 40 124 5.1 2.1 
ESR  (2-32mm/h)  90     81     
Bilirubin  (<20μmol/L)  42  11  3 4 3   8 
ALP (0.8-4.6μkat/L 
1998-2003) 
(0.6-1.8μkat/L 
2003-) 
15 5.3  3.1  5.8  3.1  2.1  0.85
GT  (<0.65μkat/L)     3.9   3.4  1.6 
AST (<0.7μkat/L)  0.86  0.28  0.25  0.5  0.250.25 0.32
ALT (<0.7μkat/L)  1.9  0.55  0.17  0.570.170.21 0.38
S. 
Creatinine 
(45-
116μmol/L) 
86  76 79 74 90 588  101
S.  Albumin (36-51g/L)    34 32 37 25 12  35 
Albuminuria 
(mg/mmol) 
<3.8 Negative 
albustix 
   303 7447
 
During follow up, he maintained normal blood 
hemoglobin concentration (Hgb), negative urine dipstick 
protein analyses and his diabetes was controlled with 
regular follow up in the outpatient clinic. In March 2005, 
the patient presented to the infectious disease clinic with 
three weeks’ history of dry cough, generalized malaise, 
fatigue, and vertigo. On admission he experienced sudden 
right lower extremity weakness diagnosed as quadriceps 
muscle mononeuritis which gradually decreased, and 
disappeared after two weeks. Chest X-ray was normal.   
Serum albumin was low (25g/L) but urine dipstick was 3+ 
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positive for albumin (Table1).  Urine albumin excretion 
quantification (albumin creatinine ratio, ACI) was 239 
mg/mmol. Renal biopsy showed nodular mesangial matrix 
deposition stain positive for Congo red (Fig. 1).   
Immunoflourescence stain for serum amyloid AA was 
positive, indicating amyloidosis secondary to longstanding 
inflammation. DNA-analysis for familial Mediterranean 
fever showed no mutation consistent with that disease. 
The angiotensin converting enzyme (ACE) level was 
normal which excluded sarcoidosis.  HIV ELISA was 
negative.  PPD-test resulted in a reaction of 14 mm, which 
was compared to a negative test five years earlier. The 
patient had received BCG vaccination in childhood.  TB-
culture of the urine and gastric lavage were also negative. 
A quantiferon test for detecting Mycobacterium 
tuberculosis was negative as well.  
 
Abdominal CT showed para-aortic lymphadenopathy 
with a clear inflammatory process near the left kidney 
(para- and peri-renal inflammation).  Chest CT showed 
four small diffuse changes in the upper and lower lobes of 
the right lung (4.5, 6, 3.5, and 25 mm respectively) 
whereas open pleural and lung biopsies proved non-
conclusive. Enlarged para-aortal lymph node fine needle 
aspirate showed reactive plasmacytosis without evidence 
of T or B cell malignancy. During medical evaluation, 
Castleman’s disease was considered, and diagnostic 
laparotomy for lymph node biopsy was performed in the 
retroperitoneal space which showed a morphological 
picture consistent with Castleman’s disease, plasma cell 
variant type (Fig. 2 A and B). The follicles were mostly 
small and atrophic and the interfollicular area contained 
large numbers of plasma cells with a polyclonal pattern.  
There were no signs of increased vascularisation or 
hyalinization nor could HHV-8 positive cells be detected. 
 
Final diagnosis 
Multicentric Castleman’s disease of plasma cell variant 
with secondary renal amyloidosis. 
 
Subsequent management course 
To decrease the proteinuria, treatment with ACE 
inhibitors was initiated. Anticoagulation prophylaxis 
therapy with warfarin was used. When initial treatment for 
Castleman’s disease with high dose prednisolone (100 
mg/day) was unsuccessful, treatment with the R-CHOP 21 
chemotherapy regime, (Rituximab, Vincristine, 
Doxorubicin, Cyclophosphamide and Prednisolone every 
21 days) was initiated. After the second course of 
chemotherapy, the patient’s condition was complicated by 
pneumonia and multiorgan system failure including acute 
renal failure requiring haemodialysis.  Pneumocystis carinii 
was diagnosed and successfully treated, with complete 
remission. 
 
Repeated earlier testing showed normal serum amyloid 
AA (5.4 mg/l) and abdominal ultrasound confirmed 
complete remission of the lymphadenopathy. Accordingly, 
remission of Castleman’s disease was concluded and no 
further chemotherapy was necessary.  Subsequently, renal 
function improved and serum creatinine decreased to 
150μmol/l. However, the patient remained severely 
nephrotic (serum albumin 10-15 g/l and albuminuria of 
Figure 1. Kidney biopsy show amyloid deposit in the glomeruli. 
Congo red.  
 
 
Figure2. Excisional Lymph node biopsy show small lymphoid 
follicles with regressive changes in germinal centre (A). The 
interfollicular areas contain large number of plasma cells (B). 
6 - 7000 mg/mmol creatinine).  In addition, due to long 
standing muscular atrophy combined with severe 
orthostatic blood pressures, the patient was unable to 
walk or even stand up independently.  ACE inhibitor 
therapy was unsuccessful in treating the patient’s 
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proteinuria, so treatment with NSAIDs was added.     
During the following three months, renal function 
deteriorated slowly and chronic haemodialysis treatment 
was initiated. The patient’s general condition improved, 
serum albumin and systolic blood pressure normalized. 
One year later the patient received a renal transplant from 
a living donor. 
Discussion 
The combination of persistent inflammation and 
radiologic findings of lymph node enlargement raised the 
possibility of lymphoproliferative disease as early as 1998. 
Fine needle aspiration biopsies of enlarged lymph nodes 
excluded TB and lymphoma diagnoses, but did not 
exclude CD. Not until seven years later after open lymph 
node biopsy was the final diagnosis of CD established. 
Unfortunately, the long standing inflammation had given 
rise to irreversible organ damage which eventually 
required renal replacement therapy. 
 
CD is a rare pathological entity among atypical 
lymphoproliferative disorders. Mediastinal and cervical 
lymph nodes are more commonly involved than   
retroperitoneal and pelvic lymph groups [4].  Diagnosis 
requires a histopathological examination of involved lymph 
node structures. The histological diagnosis is divided into 3 
basic types:  hyaline vascular (HV), plasma cell (PC) and 
mixed variant (MV) [5]. Even though 80-90% of CD cases 
are of the hyaline vascular type, many cases of 
amyloidosis have been of the plasma cell variant. 
Contrasting to this case, however, most of those have 
been localized [6].  Recently human herpes virus 8 
infection  (HHV-8) has been implicated in the aetiology of  
several cases [7]. The large amount of IL-6 produced by 
involved lymph nodes in CD contributes to the sustained 
overproduction of acute phase protein CRP and serum 
amyloid A protein (SAA) [8].  Serum AA is the precursor of 
the amyloidal AA protein in reactive amyloidosis [9]. 
Systemic amyloidosis sometimes complicates an occult CD 
where the underlying disease is diagnosed after many 
years of illness [6, 10-12].  
 
While surgical removal of the involved lymph nodes is 
curative in unicentric variant CD, there is no consensus on 
how to treat multicentric variant  CD [4, 13]. Such cases 
do not benefit from surgery and systemic treatment may 
be required to abolish the inflammation even though 
spontaneous remissions have been reported. Steroid 
treatment is usually associated with partial response and 
combination chemotherapy therapy like CHOP with 
additional Anti-CD20 (Rituximab) have also induced 
remission in some cases [2, 13-15]. In this case, two 
courses of R-CHOP were enough to establish a long-
lasting remission, but the nephrotic syndrome did not 
regress. Most likely, the kidney disease was in an 
advanced stage at the time of initiation of chemotherapy 
treatment for CD. 
 
In order to decrease the proteinuria and improve the 
nutritional status in patients with intractable nephrotic 
syndrome, bilateral nephrectomy and subsequent dialysis 
have been successful [16].  More recently, a combination 
of Angiotensin-converting enzyme inhibitors and 
prostaglandin synthetase inhibitors have been reported to 
be a successful alternative to surgery, sometimes referred 
to as “chemical nephrectomy”.  ACE inhibitors 
preferentially dilate the efferent arterioles and NSAIDs 
selectively induce vasoconstriction of the afferent 
arterioles [17]. Our patient was at first reluctant to try this 
approach. When it was finally used, there was a delayed 
effect. 
 
Summary
In summary the diagnosis of Castleman’s disease could 
easily be missed and should be considered on the 
differential diagnosis list for patients with unexplained 
chronic inflammation. Open lymph node biopsy is an 
important option to establish the diagnosis of CD.  
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